Core Viewpoint - Baiyunshan (00874) has seen a nearly 3% increase in stock price, currently at HKD 18.62, with a trading volume of HKD 62.93 million, following the announcement of a partnership agreement with Guangzhou Pharmaceutical Capital to establish the second phase of the Guangzhou Pharmaceutical Fund [1] Group 1: Company Actions - Baiyunshan announced a partnership agreement with Guangzhou Pharmaceutical Capital to invest RMB 1.4985 billion and RMB 1.5 million respectively in the establishment of the second phase of the Guangzhou Pharmaceutical Fund [1] - The company will have substantial control over the second phase of the Guangzhou Pharmaceutical Fund, and its financial performance will be included in the company's consolidated financial statements [1] Group 2: Investment Focus - The partnership aims to conduct equity investments in the biopharmaceutical sector through direct or indirect means to achieve investment returns [1] - The investment strategy will align with the company's strategic planning, focusing on sub-fund investments and direct project investments in pharmaceuticals, medical devices, and healthcare services within the biopharmaceutical and health sectors [1] Group 3: Strategic Goals - The establishment of the second phase of the Guangzhou Pharmaceutical Fund is intended to seize industry development opportunities and accelerate the company's layout in the biopharmaceutical health sector [1] - The initiative aims to enhance the company's efforts in incubating and investing in the pharmaceutical health industry [1]